Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,133.15
+0.2%
$974.59
$623.78
$1,166.29
$1.07T0.533.02 million shs4.12 million shs
Meta Platforms, Inc. stock logo
META
Meta Platforms
$593.00
$618.83
$520.26
$796.25
$1.50T1.2316.09 million shs29.62 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+2.51%+19.53%+12.37%+47.16%
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.00%-6.25%-2.73%-8.40%-15.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,133.15
+0.2%
$974.59
$623.78
$1,166.29
$1.07T0.533.02 million shs4.12 million shs
Meta Platforms, Inc. stock logo
META
Meta Platforms
$593.00
$618.83
$520.26
$796.25
$1.50T1.2316.09 million shs29.62 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+2.51%+19.53%+12.37%+47.16%
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.00%-6.25%-2.73%-8.40%-15.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.008.28% Upside
Meta Platforms, Inc. stock logo
META
Meta Platforms
2.83
Moderate Buy$840.6041.75% Upside

Current Analyst Ratings Breakdown

Latest LLY and META Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
UpgradeOutperformNeutral
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Initiated CoverageHoldBuy
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Initiated CoverageOverweight
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
DowngradeBuyNeutral
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
UpgradeUnderperformOutperform
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Initiated CoverageOutperform
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
UpgradePositive
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
DowngradeBuySell
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Set Price TargetNeutralBuy$735.00
6/2/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
UpgradeHoldStrong-Buy$735.00
(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B16.37$25.18 per share45.01$28.07 per share40.37
Meta Platforms, Inc. stock logo
META
Meta Platforms
$200.97B7.46$37.56 per share15.79$85.88 per share6.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1540.2525.431.2434.98%105.77%23.76%8/5/2026 (Estimated)
Meta Platforms, Inc. stock logo
META
Meta Platforms
$60.46B$27.5121.5616.941.0532.84%36.93%23.09%7/29/2026 (Estimated)

Latest LLY and META Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
$6.67$10.44+$3.77$10.44$55.56 billion$56.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.61%+15.18%24.58%11 Years
Meta Platforms, Inc. stock logo
META
Meta Platforms
$2.100.35%N/A7.63%1 Years

Latest LLY and META Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/28/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
quarterly$0.52500.33%6/15/20266/15/20266/25/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.24
2.35
2.35

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Meta Platforms, Inc. stock logo
META
Meta Platforms
79.91%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Meta Platforms, Inc. stock logo
META
Meta Platforms
13.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Meta Platforms, Inc. stock logo
META
Meta Platforms
78,8652.53 billion2.19 billionOptionable

Recent News About These Companies

Promising Virtual Reality Stocks To Follow Today - June 5th
Huge News for Meta Stock Investors!

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,133.14 +1.73 (+0.15%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$1,151.80 +18.66 (+1.65%)
As of 08:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Meta Platforms stock logo

Meta Platforms NASDAQ:META

$593.00 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$598.42 +5.42 (+0.91%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California